The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Drugs for Non-Small Cell Lung Cancer Market Research Report 2024

Global Drugs for Non-Small Cell Lung Cancer Market Research Report 2024

Publishing Date : Jan, 2024

License Type :
 

Report Code : 1888242

No of Pages : 100

Ask Your Query
Synopsis
The global Drugs for Non-Small Cell Lung Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Drugs for Non-Small Cell Lung Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Non-Small Cell Lung Cancer.
Report Scope
The Drugs for Non-Small Cell Lung Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Drugs for Non-Small Cell Lung Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Non-Small Cell Lung Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bristol-Myers Squibb
GlaxoSmithKline
Menarini
Sanofi
Ziopharm Oncology
Alchemia
Amgen
Apotex
BioMarin Pharmaceutical
CellAct Pharma
Cerulean Pharma
Cipla
Cornerstone Pharmaceuticals
Curis
CytRx
Eli Lilly
Exelixis
Fresenius Kabi
Genentech
Hikma Pharmaceuticals
Hospira
Intas Pharmaceuticals
Karyopharm Therapeutics
Kyowa Hakko Kirin
Ligand Pharmaceuticals
Segment by Type
Radiofrequency Ablation (RFA)
Radiation Therapy
Chemotherapy
Targeted Therapies
Immunotherapy
Segment by Application
Hospitals
Clinics
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drugs for Non-Small Cell Lung Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Radiofrequency Ablation (RFA)
1.2.3 Radiation Therapy
1.2.4 Chemotherapy
1.2.5 Targeted Therapies
1.2.6 Immunotherapy
1.3 Market by Application
1.3.1 Global Drugs for Non-Small Cell Lung Cancer Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drugs for Non-Small Cell Lung Cancer Market Perspective (2019-2030)
2.2 Drugs for Non-Small Cell Lung Cancer Growth Trends by Region
2.2.1 Global Drugs for Non-Small Cell Lung Cancer Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Drugs for Non-Small Cell Lung Cancer Historic Market Size by Region (2019-2024)
2.2.3 Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Region (2025-2030)
2.3 Drugs for Non-Small Cell Lung Cancer Market Dynamics
2.3.1 Drugs for Non-Small Cell Lung Cancer Industry Trends
2.3.2 Drugs for Non-Small Cell Lung Cancer Market Drivers
2.3.3 Drugs for Non-Small Cell Lung Cancer Market Challenges
2.3.4 Drugs for Non-Small Cell Lung Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drugs for Non-Small Cell Lung Cancer Players by Revenue
3.1.1 Global Top Drugs for Non-Small Cell Lung Cancer Players by Revenue (2019-2024)
3.1.2 Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Players (2019-2024)
3.2 Global Drugs for Non-Small Cell Lung Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Drugs for Non-Small Cell Lung Cancer Revenue
3.4 Global Drugs for Non-Small Cell Lung Cancer Market Concentration Ratio
3.4.1 Global Drugs for Non-Small Cell Lung Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs for Non-Small Cell Lung Cancer Revenue in 2023
3.5 Drugs for Non-Small Cell Lung Cancer Key Players Head office and Area Served
3.6 Key Players Drugs for Non-Small Cell Lung Cancer Product Solution and Service
3.7 Date of Enter into Drugs for Non-Small Cell Lung Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Drugs for Non-Small Cell Lung Cancer Breakdown Data by Type
4.1 Global Drugs for Non-Small Cell Lung Cancer Historic Market Size by Type (2019-2024)
4.2 Global Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Type (2025-2030)
5 Drugs for Non-Small Cell Lung Cancer Breakdown Data by Application
5.1 Global Drugs for Non-Small Cell Lung Cancer Historic Market Size by Application (2019-2024)
5.2 Global Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Drugs for Non-Small Cell Lung Cancer Market Size (2019-2030)
6.2 North America Drugs for Non-Small Cell Lung Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2019-2024)
6.4 North America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Drugs for Non-Small Cell Lung Cancer Market Size (2019-2030)
7.2 Europe Drugs for Non-Small Cell Lung Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Country (2019-2024)
7.4 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size (2019-2030)
8.2 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Region (2019-2024)
8.4 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Drugs for Non-Small Cell Lung Cancer Market Size (2019-2030)
9.2 Latin America Drugs for Non-Small Cell Lung Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2019-2024)
9.4 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size (2019-2030)
10.2 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Country (2019-2024)
10.4 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Detail
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Introduction
11.1.4 Bristol-Myers Squibb Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Detail
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Introduction
11.2.4 GlaxoSmithKline Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.2.5 GlaxoSmithKline Recent Development
11.3 Menarini
11.3.1 Menarini Company Detail
11.3.2 Menarini Business Overview
11.3.3 Menarini Drugs for Non-Small Cell Lung Cancer Introduction
11.3.4 Menarini Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.3.5 Menarini Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Detail
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Drugs for Non-Small Cell Lung Cancer Introduction
11.4.4 Sanofi Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.4.5 Sanofi Recent Development
11.5 Ziopharm Oncology
11.5.1 Ziopharm Oncology Company Detail
11.5.2 Ziopharm Oncology Business Overview
11.5.3 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Introduction
11.5.4 Ziopharm Oncology Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.5.5 Ziopharm Oncology Recent Development
11.6 Alchemia
11.6.1 Alchemia Company Detail
11.6.2 Alchemia Business Overview
11.6.3 Alchemia Drugs for Non-Small Cell Lung Cancer Introduction
11.6.4 Alchemia Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.6.5 Alchemia Recent Development
11.7 Amgen
11.7.1 Amgen Company Detail
11.7.2 Amgen Business Overview
11.7.3 Amgen Drugs for Non-Small Cell Lung Cancer Introduction
11.7.4 Amgen Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.7.5 Amgen Recent Development
11.8 Apotex
11.8.1 Apotex Company Detail
11.8.2 Apotex Business Overview
11.8.3 Apotex Drugs for Non-Small Cell Lung Cancer Introduction
11.8.4 Apotex Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.8.5 Apotex Recent Development
11.9 BioMarin Pharmaceutical
11.9.1 BioMarin Pharmaceutical Company Detail
11.9.2 BioMarin Pharmaceutical Business Overview
11.9.3 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Introduction
11.9.4 BioMarin Pharmaceutical Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.9.5 BioMarin Pharmaceutical Recent Development
11.10 CellAct Pharma
11.10.1 CellAct Pharma Company Detail
11.10.2 CellAct Pharma Business Overview
11.10.3 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Introduction
11.10.4 CellAct Pharma Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.10.5 CellAct Pharma Recent Development
11.11 Cerulean Pharma
11.11.1 Cerulean Pharma Company Detail
11.11.2 Cerulean Pharma Business Overview
11.11.3 Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Introduction
11.11.4 Cerulean Pharma Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.11.5 Cerulean Pharma Recent Development
11.12 Cipla
11.12.1 Cipla Company Detail
11.12.2 Cipla Business Overview
11.12.3 Cipla Drugs for Non-Small Cell Lung Cancer Introduction
11.12.4 Cipla Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.12.5 Cipla Recent Development
11.13 Cornerstone Pharmaceuticals
11.13.1 Cornerstone Pharmaceuticals Company Detail
11.13.2 Cornerstone Pharmaceuticals Business Overview
11.13.3 Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
11.13.4 Cornerstone Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.13.5 Cornerstone Pharmaceuticals Recent Development
11.14 Curis
11.14.1 Curis Company Detail
11.14.2 Curis Business Overview
11.14.3 Curis Drugs for Non-Small Cell Lung Cancer Introduction
11.14.4 Curis Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.14.5 Curis Recent Development
11.15 CytRx
11.15.1 CytRx Company Detail
11.15.2 CytRx Business Overview
11.15.3 CytRx Drugs for Non-Small Cell Lung Cancer Introduction
11.15.4 CytRx Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.15.5 CytRx Recent Development
11.16 Eli Lilly
11.16.1 Eli Lilly Company Detail
11.16.2 Eli Lilly Business Overview
11.16.3 Eli Lilly Drugs for Non-Small Cell Lung Cancer Introduction
11.16.4 Eli Lilly Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.16.5 Eli Lilly Recent Development
11.17 Exelixis
11.17.1 Exelixis Company Detail
11.17.2 Exelixis Business Overview
11.17.3 Exelixis Drugs for Non-Small Cell Lung Cancer Introduction
11.17.4 Exelixis Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.17.5 Exelixis Recent Development
11.18 Fresenius Kabi
11.18.1 Fresenius Kabi Company Detail
11.18.2 Fresenius Kabi Business Overview
11.18.3 Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Introduction
11.18.4 Fresenius Kabi Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.18.5 Fresenius Kabi Recent Development
11.19 Genentech
11.19.1 Genentech Company Detail
11.19.2 Genentech Business Overview
11.19.3 Genentech Drugs for Non-Small Cell Lung Cancer Introduction
11.19.4 Genentech Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.19.5 Genentech Recent Development
11.20 Hikma Pharmaceuticals
11.20.1 Hikma Pharmaceuticals Company Detail
11.20.2 Hikma Pharmaceuticals Business Overview
11.20.3 Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
11.20.4 Hikma Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.20.5 Hikma Pharmaceuticals Recent Development
11.21 Hospira
11.21.1 Hospira Company Detail
11.21.2 Hospira Business Overview
11.21.3 Hospira Drugs for Non-Small Cell Lung Cancer Introduction
11.21.4 Hospira Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.21.5 Hospira Recent Development
11.22 Intas Pharmaceuticals
11.22.1 Intas Pharmaceuticals Company Detail
11.22.2 Intas Pharmaceuticals Business Overview
11.22.3 Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
11.22.4 Intas Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.22.5 Intas Pharmaceuticals Recent Development
11.23 Karyopharm Therapeutics
11.23.1 Karyopharm Therapeutics Company Detail
11.23.2 Karyopharm Therapeutics Business Overview
11.23.3 Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Introduction
11.23.4 Karyopharm Therapeutics Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.23.5 Karyopharm Therapeutics Recent Development
11.24 Kyowa Hakko Kirin
11.24.1 Kyowa Hakko Kirin Company Detail
11.24.2 Kyowa Hakko Kirin Business Overview
11.24.3 Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Introduction
11.24.4 Kyowa Hakko Kirin Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.24.5 Kyowa Hakko Kirin Recent Development
11.25 Ligand Pharmaceuticals
11.25.1 Ligand Pharmaceuticals Company Detail
11.25.2 Ligand Pharmaceuticals Business Overview
11.25.3 Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
11.25.4 Ligand Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2019-2024)
11.25.5 Ligand Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock